CBD’s Main Drug-Liking Result and a Secondary Liking Measure Were Not Identical
A human abuse-potential trial summarized in the supplied review found placebo-like CBD results on its primary drug-liking measure, alongside small increases on a secondary overall-liking measure at two doses. Those findings should remain separately identified.
The trial included active comparators
Healthy recreational polydrug users participated in a randomized, placebo- and active-controlled crossover trial. The review describes single doses of CBD compared with dronabinol and alprazolam. Active comparators matter because a trial that detects their expected signals is more informative than a collection of null comparisons without evidence that the procedure could detect a response.
The primary outcome did not show the comparator pattern
The highest maximum drug-liking score occurred with the higher dronabinol dose. Dronabinol and alprazolam produced statistically significant signals, while CBD scores remained in the neutral placebo range on the primary endpoint. This result addresses the measured acute subjective response, rather than the incidence of dependence after months of use.
Secondary outcomes supplied qualifications
The review reports no CBD separation from placebo on willingness to take the drug again, but small increases at two doses on overall drug liking. These are differently framed measures. The secondary signals should neither be omitted nor substituted for the prespecified primary result. They do not mean every CBD outcome was indistinguishable from placebo.
The interpretation concerns this preparation and trial
The review also describes no CBD-related cognitive impairment in this experiment. That does not turn a single-dose study into evidence about every dose, interaction or commercial mixture. Its central contribution is a controlled acute abuse-potential comparison with both favorable findings and a limited secondary signal, rather than an absolute claim that no participant can experience any subjective effect from CBD.
Related analysis: reinforcement, motivation and withdrawal as separate outcomes.
Research cited
This analysis uses the research synthesis in Heal DJ, Gosden J and Smith SL (2024), A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids, Frontiers in Psychiatry.
The study discussed in that review is also identified by DOI: 10.1016/j.yebeh.2018.07.027.
